Torsemide (Torsemide) - Summary

TORSEMIDE SUMMARY

Torsemide is a diuretic of the pyridine-sulfonylurea class.

Torsemide tablets are indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials.

Torsemide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

See all indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Torsemide

Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. [2005]
Diuretic therapy in ARF (acute renal failure) is mainly done with loop diuretics, first of all furosemide... Serum creatinine and blood urea nitrogen elimination were less pronounced in the furosemide group.

more studies >>

Clinical Trials Related to Torsemide

Bioavailability Study of Torsemide Tablets Under Fed Conditions [Completed]
To compare the single-dose bioavailability of Torsemide tablets with Demadex

Bioavailability Study of Torsemide Tablets Under Fasting Conditions [Completed]
To compare the single-dose bioavailability of Torsemide tablets with Demadex

Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension. [Completed]
Primary objective: To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension.

Secondary objectives: To evaluate the safety and tolerability of Torsemide-PR.

Bioequivalency Study of Torsemide Tablets Under Fasting Conditions [Completed]
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.

Bioequivalency Study of Torsemide Tablets Under Fed Conditions [Completed]
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.

more trials >>